STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 GEORGIA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, GEORGIA, 2004

		ı	Number of Be	neficiaries				١	Number of Be	nefit Months		
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	1,503,848	3,737	156,897	302,427	1,038,063	2,724	13,324,267	33,873	1,664,762	2,162,337	9,436,905	26,390
Age												
5 and younger	490,540	0	11,036	83	479,419	2	4,340,719	0	116,207	466	4,224,044	2
6-14	434,047	0	24,239	235	409,573	0	4,155,228	0	271,271	1,404	3,882,553	0
15-20	202,165	0	15,521	38,127	148,430	87	1,769,478	0	170,704	272,991	1,325,072	711
21-44	295,285	0	44,101	249,222	598	1,364	2,263,922	0	471,074	1,774,655	4,886	13,307
45-64	75,824	0	59,812	14,730	22	1,260	736,672	0	611,641	112,623	137	12,271
65-74	3,424	1,519	1,871	19	4	11	34,256	13,501	20,493	135	28	99
75-84	1,765	1,489	271	4	1	0	17,030	14,066	2,921	31	12	0
85 and older	796	729	46	6	15	0	6,955	6,306	451	27	171	0
Unknown	2	0	0	1	1	0		0	0	5	2	0
Gender												
Female	876,145	2,434	80,097	277,491	513,402	2,721	7,599,984	22,164	861,831	2,004,943	4,684,669	26,377
Male	627,650	1,302	76,800	24,936	524,609	3	7 5,724,002	11,708	802,931	157,394	4,751,956	13
Unknown	53	1	0	0	52	0	281	1	0	0	280	0
Race												
White	615,507	1,384	53,911	135,977	422,757	1,478	5,192,291	11,435	560,598	885,926	3,719,954	14,378
African American	748,707	979	69,046	157,817	519,931	934	6,897,166	8,618	740,085	1,230,028	4,909,614	8,821
Other/unknown	139,634	1,374	33,940	8,633	95,375	312	1,234,810	13,820	364,079	46,383	807,337	3,191
Use of Nursing Facilities ^c												
Entire year	2,191	558	1,630	2	1	0	22,475	5,454	17,015	5	1	0
Part year	1,336	265	1,059	7	2	3	13,239	2,365	10,789	54	11	20
None	1,500,321	2,914	154,208	302,418	1,038,060	2,721	13,288,553	26,054	1,636,958	2,162,278	9,436,893	26,370
Maintenance Assistance Status												
Cash	517,508	1,391	133,609	136,443	246,065	0	4,921,279	15,197	1,470,661	1,063,239	2,372,182	0
Medically needy	4,205	876	3,273	4	52	0	23,707	6,689	16,841	5	172	0
Poverty-related	734,957	27	72	114,532	617,602	2,724	6,278,461	237	684	655,633	5,595,517	26,390
Other/unknown	247,178	1,443	19,943	51,448	174,344	0	2,100,820	11,750	176,576	443,460	1,469,034	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,503,848	3,737	156,897	302,427	1,038,063	2,724	13,324,267	33,873	1,664,762	2,162,337	9,436,905	26,390
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0

0

0

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{9, b} NONDUAL BENEFICIARIES, GEORGIA, 2004

Characteristics All Age 5 and younger 6-14 15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	67.1 56.5 59.1 70.2 77.0 80.5 77.3 76.0 0.0	Mean Number of Rx 7.9 5.1 4.7 5.5 10.6 37.5 39.0 35.3 34.6 0.0	Mean Rx \$ \$452 225 301 337 620 2,327 2,086 1,762 1,544	\$ per Rx \$57 44 64 62 59 62 53 50	Medicaid FFS \$° \$2,689 1,908 1,398 2,304 4,006 10,223 13,028	of All Medicaid FFS \$ ^d 16.8 % 11.8 21.5 14.6 15.5 22.8	Number of Beneficiaries 1,503,848 490,540 434,047 202,165 295,285 75,824
All Age 5 and younger 6-14 15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	64.1 % 67.1 56.5 59.1 70.2 77.0 80.5 77.3 76.0 0.0	7.9 5.1 4.7 5.5 10.6 37.5 39.0 35.3 34.6	\$452 225 301 337 620 2,327 2,086 1,762 1,544	\$57 44 64 62 59 62 53	\$2,689 1,908 1,398 2,304 4,006 10,223 13,028	16.8 % 11.8 21.5 14.6 15.5	1,503,848 490,540 434,047 202,165 295,285
Age 5 and younger 6-14 15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	67.1 56.5 59.1 70.2 77.0 80.5 77.3 76.0 0.0	5.1 4.7 5.5 10.6 37.5 39.0 35.3 34.6	225 301 337 620 2,327 2,086 1,762 1,544	44 64 62 59 62 53	1,908 1,398 2,304 4,006 10,223 13,028	11.8 21.5 14.6 15.5	490,540 434,047 202,165 295,285
5 and younger 6-14 15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	56.5 59.1 70.2 77.0 80.5 77.3 76.0 0.0	4.7 5.5 10.6 37.5 39.0 35.3 34.6	301 337 620 2,327 2,086 1,762 1,544	64 62 59 62 53	1,398 2,304 4,006 10,223 13,028	21.5 14.6 15.5	434,047 202,165 295,285
6-14 15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	56.5 59.1 70.2 77.0 80.5 77.3 76.0 0.0	4.7 5.5 10.6 37.5 39.0 35.3 34.6	301 337 620 2,327 2,086 1,762 1,544	64 62 59 62 53	1,398 2,304 4,006 10,223 13,028	21.5 14.6 15.5	434,047 202,165 295,285
15-20 21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	59.1 70.2 77.0 80.5 77.3 76.0 0.0	5.5 10.6 37.5 39.0 35.3 34.6	337 620 2,327 2,086 1,762 1,544	62 59 62 53	2,304 4,006 10,223 13,028	14.6 15.5	202,165 295,285
21-44 45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	70.2 77.0 80.5 77.3 76.0 0.0	10.6 37.5 39.0 35.3 34.6	620 2,327 2,086 1,762 1,544	59 62 53	4,006 10,223 13,028	15.5	295,285
45-64 65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	77.0 80.5 77.3 76.0 0.0	37.5 39.0 35.3 34.6	2,327 2,086 1,762 1,544	62 53	10,223 13,028		
65-74 75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	80.5 77.3 76.0 0.0	39.0 35.3 34.6	2,086 1,762 1,544	53	13,028	22.8	75.824
75-84 85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	77.3 76.0 0.0	35.3 34.6	1,762 1,544				
85 and older Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	76.0 0.0	34.6	1,544	50		16.0	3,424
Unknown Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender	0.0				11,076	15.9	1,765
Basis of Eligibility ^e Aged Disabled Adults Children Unknown Gender		0.0		45	15,671	9.9	796
Aged Disabled Adults Children Unknown Gender	70.0		0	0	906	0.0	2
Disabled Adults Children Unknown Gender	70.0						
Adults Children Unknown Gender	76.3	32.6	1,638	50	11,928	13.7	3,737
Children Unknown Gender	76.2	28.7	2,181	76	10,109	21.6	156,897
Unknown Gender	70.0	8.1	331	41	2,916	11.3	302,427
Gender	60.5	4.5	220	48	1,445	15.2	1,038,063
	82.4	21.2	1,515	72	11,506	13.2	2,724
Female	66.5	8.7	451	52	2,794	16.1	876,145
Male	60.9	6.8	454	67	2,542	17.9	627,650
Unknown	28.3	2.0	109	55	720	15.1	53
Race							
White	68.2	9.3	521	56	2,906	17.9	615,507
African American	61.3	6.5	359	56	2,309	15.5	748,707
Other/unknown	61.1	9.2	651	71	3,768	17.3	139,634
Use of Nursing							
Facilities ^f							
Entire year	96.9	74.8	4,581	61	48,656	9.4	2,191
Part year	96.5	67.4	4,333	64	51,102	8.5	1,336
None	64.0	7.7	443	57	2,579	17.2	1,500,321
Maintenance Assistance Status							
Cash	67.8	12.8	827	65	3,969	20.8	517,508
Medically needy	65.5	21.2	1,622	77	13,854	11.7	4,205
Poverty related	60.5	4.5	201	45	1,581	12.7	734,957
Other/unknown		7.4	395	53	3,112	12.7	247,178

Table ND3 Nondual Beneficiaries

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving fost care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, GEORGIA, 2004

					N	umber of Rx, Per	centage with:			_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	A Mean Rx \$	Rx \$ as a centage of II Medicaid FFS \$ ^c	None	0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.9	\$51	16.8 %	35.9 %	48.6 %	7.4 %	5.7 %	1.9 %	0.4 %	\$304	1,503,848	13,324,267
Age												
5 and younger	0.6	26	11.8	32.9	57.3	6.9	2.8	0.2	0.0	216	490,540	4,340,719
6-14	0.5	31	21.5	43.5	47.9	4.9	3.2	0.4	0.0	146	434,047	4,155,228
15-20	0.6	38	14.6	40.9	47.5	6.8	4.0	0.7	0.1	263	202,165	1,769,478
21-44	1.4	81	15.5	29.8	44.6	11.6	10.3	3.2	0.5	523	295,285	2,263,922
45-64	3.9	240	22.8	23.0	17.7	10.0	24.4	18.9	6.0	1,052	75,824	736,672
65-74	3.9	209	16.0	19.5	16.7	10.8	27.1	20.8	5.1	1,302	3,424	34,256
75-84	3.7	183	15.9	22.7	15.8	10.0	27.4	19.3	4.9	1,148	1,765	17,030
85 and older	4.0	177	9.9	24.0	14.3	7.7	25.6	23.4	5.0	1,794	796	6,955
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	259	2	7
Basis of Eligibility ^e												
Aged	3.6	181	13.7	23.7	17.0	11.2	25.5	18.6	4.0	1,316	3,737	33,873
Disabled	2.7	206	21.6	23.8	28.8	10.9	20.4	12.5	3.6	953	156,897	1,664,762
Adults	1.1	46	11.3	30.0	47.8	11.6	8.4	2.0	0.2	408	302,427	2,162,337
Children	0.5	24	15.2	39.5	52.0	5.6	2.6	0.2	0.0	159	1,038,063	9,436,905
Unknown	2.2	156	13.2	17.6	35.6	14.3	22.3	9.1	1.1	1,188	2,724	26,390
Gender												
Female	1.0	52	16.1	33.5	49.3	8.0	6.2	2.3	0.6	322	876,145	7,599,984
Male	0.7	50	17.9	39.1	47.7	6.6	5.0	1.4	0.2	279	627,650	5,724,002
Unknown	0.4	21	15.1	71.7	22.6	1.9	3.8	0.0	0.0	136	53	281
Race												
White	1.1	62	17.9	31.8	49.0	8.9	7.2	2.5	0.7	345	615,507	5,192,291
African American	0.7	39	15.5	38.7	49.2	6.2	4.3	1.3	0.2	251	748,707	6,897,166
Other/unknown	1.0	74	17.3	38.9	44.1	7.2	6.5	2.6	0.7	426	139,634	1,234,810
Use of Nursing Facilities ^f												
Entire year	7.3	447	9.4	3.1	4.0	5.8	25.1	41.4	20.7	4,743	2,191	22,475
Part year	6.8	437	8.5	3.5	7.4	7.1	27.6	36.5	17.9	5,157	1,336	13,239
None	0.9	50	17.2	36.0	48.7	7.4	5.7	1.8	0.4	291	1,500,321	13,288,553
Maintenance Assistance Status												
Cash	1.3	87	20.8	32.2	44.8	8.2	9.3	4.3	1.1	417	517,508	4,921,279
Medically needy	3.8	288	11.7	34.5	12.5	8.9	23.7	16.4	4.0	2,457	4,205	23,707
Poverty related	0.5	24	12.7	39.5	50.8	6.4	3.0	0.3	0.0	185	734,957	6,278,461
Other/unknown	0.9	47	12.7	32.7	50.8	8.6	6.0	1.5	0.3	366	247,178	2,100,820

Table ND4 Nondual Beneficiaries

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

NONDUAL BENEFICIARIES, GEORGIA, 2004

Beneficiary		All Rx		Patented Bra	and-Name	Drugs	Off-Patent B	Brand-Name	Drugs	Gen	eric Drugs	
<u>-</u>	Number			Number			Number			Number		
Beneficiary Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.9	\$51	\$57	0.4	\$39	\$109	0.1	\$3	\$50	0.5	\$9	\$19
Age												
5 and younger	0.6	26	44	0.2	18	92	0.1	2	34	0.3	5	15
6-14	0.5	31	64	0.3	26	98	0.0	2	48	0.2	4	21
15-20	0.6	38	62	0.3	30	111	0.0	2	52	0.3	6	20
21-44	1.4	81	59	0.5	61	125	0.1	5	58	0.8	15	19
45-64	3.9	240	62	1.5	179	118	0.2	15	75	2.1	45	21
65-74	3.9	209	53	1.7	159	96	0.2	10	50	2.0	39	19
75-84	3.7	183	50	1.6	140	88	0.2	9	47	1.8	33	18
85 and older	4.0	177	45	1.5	130	84	0.2	9	36	2.1	37	17
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility ^d												
Aged	3.6	181	50	1.6	138	88	0.2	9	45	1.8	33	18
Disabled	2.7	206	76	1.1	161	142	0.2	12	79	1.4	32	23
Adults	1.1	46	41	0.4	32	85	0.1	3	41	0.7	11	16
Children	0.5	24	48	0.2	18	87	0.0	2	36	0.2	4	17
Unknown	2.2	156	72	0.8	124	149	0.1	7	68	1.2	25	20
Gender												
Female	1.0	52	52	0.4	39	101	0.1	4	49	0.5	10	18
Male	0.7	50	67	0.3	39	121	0.1	3	53	0.4	7	20
Unknown	0.4	21	55	0.2	17	92	0.1	2	32	0.1	2	14
Race												
White	1.1	62	56	0.4	47	104	0.1	4	52	0.6	11	19
African American	0.7	39	56	0.3	30	108	0.1	3	46	0.4	7	18
Other/unknown	1.0	74	71	0.4	59	133	0.1	4	57	0.5	11	20
Use of Nursing Facilities ^e												
Entire year	7.3	447	61	2.7	332	124	0.6	31	53	4.0	83	21
Part year	6.8	437	64	2.5	326	129	0.5	32	64	3.8	79	21
None	0.9	50	57	0.4	38	109	0.1	3	50	0.5	9	19
Maintenance Assistance												
Status												
Cash	1.3	87	65	0.5	67	124	0.1	5	63	0.7	15	20
Medically needy	3.8	288	77	1.5	216	142	0.2	14	74	2.0	58	29
Poverty related	0.5	24	45	0.2	17	83	0.0	2	35	0.3	4	17
Other/unknown	0.9	47	53	0.4	36	101	0.1	3	44	0.4	8	17

Table ND5 Nondual Beneficiaries

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES. GEORGIA. 2004

			per Be		\$ per E	Benefit M Use		nong		\$ pe	r Rx			_		Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.1	\$14	\$10	\$1	\$3	\$52	\$101	\$57	\$19	1,721,548	\$89,985,167	638,985	42.5 %	6,510,860
Biologicals	0.6	0.5	0.0	0.0	789	675	9	105	1423	1,285	4,228	3,893	17,273	24,585,418	3,461	0.2	31,165
Antineoplastic Agents	0.5	0.2	0.0	0.3	126	101	2	23	249	670	151	67	26,063	6,484,384	4,948	0.3	51,533
Endocrine/Metabolic Drugs	0.4	0.2	0.1	0.2	18	13	2	3	48	86	30	19	885,641	42,372,884	231,632	15.4	2,345,294
Cardiovascular Agents	1.1	0.5	0.0	0.6	43	33	1	9	38	70	34	14	1,155,763	43,759,825	98,923	6.6	1,025,219
Respiratory Agents	0.4	0.2	0.0	0.2	18	14	1	3	44	75	28	17	2,251,282	99,632,173	547,445	36.4	5,628,205
Gastrointestinal Agents	0.4	0.1	0.0	0.2	22	17	1	4	60	125	72	19	515,088	30,790,060	134,834	9.0	1,373,665
Genitourinary Agents	0.2	0.1	0.0	0.1	9	6	2	2	43	64	38	20	172,745	7,452,835	81,683	5.4	785,914
CNS Drugs	0.7	0.4	0.0	0.3	68	59	2	7	96	159	82	23	1,215,697	116,816,281	166,350	11.1	1,725,065
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.6	0.5	0.0	0.1	53	50	0	3	82	90	55	35	414,551	33,998,333	59,841	4.0	642,292
Neurological Agents	0.5	0.4	0.0	0.1	161	159	0	2	310	356	61	27	16,148	5,004,073	2,908	0.2	31,157
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	14	9	1	4	33	122	119	13	1,377,811	46,143,757	337,002	22.4	3,383,198
Neuromuscular Agents	0.6	0.2	0.1	0.3	50	34	9	8	79	139	110	25	619,862	49,175,714	92,745	6.2	974,844
Nutritional Products	0.3	0.1	0.0	0.2	5	1	1	3	15	17	13	14	267,886	3,967,107	89,643	6.0	801,980
Hematological Agents	0.5	0.2	0.1	0.2	161	146	3	12	302	705	40	47	99,312	29,997,012	18,214	1.2	186,577
Topical Products	0.2	0.1	0.0	0.1	10	7	1	3	42	72	46	21	1,018,887	42,748,684	402,944	26.8	4,160,931
Miscellaneous Products	0.2	0.1	0.0	0.1	27	17	6	4	145	150	410	65	42,659	6,206,222	22,013	1.5	231,866
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	26	0	0	0	45,166	1,176,897	23,263	1.5	251,857
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	11,863,382	680,296,826	n.a.	n.a.	n.a.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}

NONDUAL BENEFICIARIES, GEORGIA, 2004

			Users		Ar	nong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx : \$ per Rx	\$ per Benefit Month
ANTIPSYCHOTICS	\$75,990,933	58,420	3.9 %	647,384	0.5	\$215	\$117
ANTIASTHMATIC	55,230,400	307,474	20.4	3,268,161	0.3	66	17
ANTICONVULSANT	41,729,103	58,356	3.9	635,770	0.6	107	66
ANTIDEPRESSANTS	35,394,051	126,822	8.4	1,324,737	0.4	61	27
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	33,998,333	71,578	4.8	787,709	0.5	82	43
DERMATOLOGICAL	31,414,086	406,231	27.0	4,286,471	0.2	46	7
ANTIVIRAL	29,346,580	25,255	1.7	260,680	0.3	331	113
PASSIVE IMMUNIZING AGENTS	24,585,383	3,420	0.2	30,844	0.6	1,424	797
ANALGESICS - Narcotic	22,428,724	342,029	22.7	3,474,016	0.2	27	6
MISC. HEMATOLOGICAL	21,184,318	6,186	0.4	66,919	0.6	559	317
Total	371,301,911	1,405,771		14,782,691	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7 Nondual Beneficiaries

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c}

NONDUAL BENEFICIARIES, GEORGIA, 2004

	All Top 10 Dru	ug Groups		ANTIPS	SYCHOTICS				ANTIA	STHMATIC		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month
All	4,262,470	\$371,301,911	58,420	3.9 %	647,384	0.5	\$117	307,474	20.4 %	3,268,161	0.3	\$17
Female	2,515,498	191,826,489	31,277	3.6	343,303	0.5	109	157,775	18.0	1,671,429	0.3	17
Disabled	1,038,970	100,758,759	18,852	23.5	216,522	0.6	132	33,343	41.6	381,213	0.4	28
E and younger	19,896	4,032,467	72	1.6	823	0.4	58	2,482	55.4	28,058	0.3	25
5 and younger	60,465	6,169,938	1,111	13.5	12,993	0.6	107	2,874	35.0	33,527	0.3	23
6-14	43,510	4,798,706	1,109	18.5	12,896	0.5	116	1,372	22.9	15,823	0.3	20
15-20	312,221	33,926,234	7,464	31.3	85,593	0.6	131	7,519	31.6	86,180	0.3	22
21-44	584,271	50,456,411	8,780	24.4	100,658	0.6	139	18,442	51.2	210,281	0.5	32
45-64	16,586	1,244,703	287	21.3	3,248	0.6	126	591	43.9	6,635	0.5	31
65-74	1,811	118,634	23	12.1	262	0.8	109	55	28.9	635	0.4	26
75-84	210	11,666	6	15.8	49	0.7	85	8	21.1	74	0.2	7
85 and older Other Eligibles	1,476,528	91,067,730	12,425	1.6	126,781	0.4	69	124,432	15.6	1,290,216	0.2	14
Other Engines	300,333	22,240,675	253	0.1	2,768	0.3	52	54,833	23.2	574,522	0.2	13
5 and younger	314,323	21,805,225	2,824	1.4	31,574	0.5	82	32,874	16.1	356,139	0.2	15
6-14	180,807	10,448,389	2,232	2.0	23,600	0.4	77	11,506	10.4	118,904	0.2	12
15-20	590,756	30,781,209	6,017	2.6	58,061	0.3	57	22,102	9.6	209,461	0.3	14
21-44	72,260	4,570,565	733	5.9	6,938	0.4	64	2,548	20.5	25,170	0.3	22
45-64	6,125	442,719	108	10.8	1,159	0.7	120	195	19.6	2,095	0.5	29
65-74	7,516	491,240	138	14.3	1,465	0.7	96	243	25.2	2,615	0.4	21
75-84	4,408	287,708	120	23.2	1,216	0.6	85	131	25.3	1,310	0.4	22
85 and older	7,700	201,100	120	20.2	1,210	0.0	00	101	20.0	1,010	0.4	
Male	1,746,932	179,471,518	27,142	4.3	304,069	0.6	127	149,695	23.9	1,596,686	0.3	17
Disabled	716,818	97,380,040	16,843	21.9	193,027	0.6	147	22,560	29.4	254,553	0.4	27
	32,940	6,592,392	293	4.5	3,389	0.5	72	4,255	64.9	48,411	0.3	23
5 and younger	144,661	17,391,786	3,571	22.3	41,552	0.6	114	5,737	35.8	66,818	0.3	22
6-14	71,320	12,198,773	2,307	24.2	26,699	0.6	133	1,890	19.8	22,020	0.3	24
15-20	200,567	33,517,499	6,403	31.6	73,378	0.7	171	2,653	13.1	30,031	0.4	23
21-44	262,075	27,246,363	4,161	17.5	46,844	0.7	152	7,815	32.8	85,027	0.5	35
45-64	4,710	395,989	97	18.5	1,055	0.7	149	189	36.1	2,018	0.5	38
65-74	523	36,569	11	13.6	110	0.7	150	21	25.9	228	0.5	34
75-84	22	669	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	1,030,114	82,091,478	10,299	1.9	111,042	0.5	93	127,135	23.1	1,342,133	0.2	15
Other Engines	352,458	27,537,452	613	0.3	6,797	0.4	61	73,834	30.4	771,081	0.2	14
5 and younger	470,464	37,300,492	6,289	3.1	69,477	0.5	93	42,952	20.9	464,803	0.2	16
6-14	126,023	11,862,737	2,497	3.3	26,366	0.5	104	8,039	10.5	85,039	0.2	14
15-20	55,298	3,393,841	604	2.9	5,547	0.3	73	1,360	6.5	12,305	0.3	18
21-44	16,369	1,354,855	140	3.9	1,349	0.5	105	562	15.6	5,012	0.4	27
45-64	3,501	262,634	45	8.1	477	0.7	136	137	24.6	1,386	0.4	27
65-74	4,109	273,509	75	14.1	722	0.7	99	172	32.4	1,757	0.4	31
75-84	1,892	105,958	36	15.5	307	0.7	84	79	34.1	750	0.5	22
85 and older	1,032	100,900	30	10.0	307	0.0	04	13	J T . I	130	0.0	22
Unknown	40	3,904	1	1.8	12	0.6	173	4	7.3	46	0.1	4

Table ND7A Nondual Beneficiaries

- a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7A Nondual Beneficiaries

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND $AGE^{a, b, c}$ NONDUAL BENEFICIARIES, GEORGIA, 2004

		ANTICC	NVULSANT				ANTIDE	PRESSANTS			STIMULA	NTS/ANTI-	OBESITY/ANG	OREXIAN	ITS
Beneficiary	Number of	Users as % of All	Number of Benefit Months Among	of Rx per Benefit	Mean Rx \$ per Benefit	Number of	Users as % of All	Number of Benefit Months Among	of Rx per Benefit	Mean Rx \$ per Benefit	Number of	Users as % of All	Number of Benefit Months Among	of Rx per Benefit	Rx \$ per Benefit
Characteristics All	Users 58,356	3.9 %	Users 635,770	Month 0.6	Month \$66	Users 126,822	8.4 %	Users 1,324,737	Month 0.4	Month \$27	Users 71,578	Benes 4.8 %	Users 787,709	Month 0.5	Month \$43
Female	36,145	4.1	390,759	0.6	63	93,765	10.7	968,796	0.4	27	21,359	2.4	235,416	0.5	·
Disabled	20,708	25.9	236,831	0.7	74	35,956	44.9	409,900	0.5	32	3,817	4.8	44,355	0.5	45
	509	11.4	5,743	0.8	95	36	0.8	422	0.3	12	139	3.1	1,605	0.3	25
5 and younger	1,570	19.1	18,393	0.8	96	1,017	12.4	11,875	0.5	24	2,184	26.6	25,462	0.6	43
6-14	1,203	20.1	13,896	0.8	108	1,376	23.0	15,887	0.5	29	672	11.2	7,826	0.5	44
15-20	7,319	30.7	83,816	0.7	79	12,341	51.8	140,628	0.5	31	424	1.8	4,819	0.4	53
21-44	9,797	27.2	111,500	0.6	64	20,664	57.4	235,208	0.6	34	395	1.1	4,615	0.5	60
45-64	273	20.3	3,072	0.6	39	466	34.6	5,247	0.6	30	3	0.2	28	0.7	29
65-74	35	18.4	387	0.7	56	52	27.4	593	0.6	33	0	0.0	0	0.0	
75-84	2	5.3	24	1.0	35	4	10.5	40	0.6	26	0	0.0	0	0.0	0
85 and older Other Eligibles	15.437	1.9	153,928	0.4	45	57.809	7.3	558.896	0.4	23	17,542	2.2	191.061	0.5	41
Other Eligibles	629	0.3	6,868	0.4	48	244	0.1	2,703	0.4	7	975	0.4	10,941	0.3	25
5 and younger	1,930	0.9	21,093	0.5	63	5,311	2.6	58,548	0.4	21	13,164	6.4	144,378	0.5	42
6-14	1,955	1.8	20,076	0.5	56	8,769	8.0	89,016	0.3	21	2.218	2.0	24.062	0.5	44
15-20	9,383	4.1	90,512	0.3	39	38,444	16.7	359,525	0.3	23	1,065	0.5	10,514	0.4	45
21-44	1,259	10.1	12,488	0.4	42	4,432	35.7	42,924	0.5	30	116	0.9	1,134	0.4	53
45-64	118	11.8	1,284	0.6	46	206	20.7	2,156	0.5	30	0	0.0	0	0.0	0
65-74	109	11.3	1,101	0.8	44	246	25.5	2,100	0.6	30	3	0.3	20	0.5	52
75-84	54	10.4	506	0.7	32	157	30.3	1,521	0.7	39	1	0.2	12	0.4	56
85 and older	34	10.4	300	0.7	32	107	50.5	1,021	0.7	33	'	0.2	12	0.4	30
Male	22,211	3.5	245,011	0.7	70	33,056	5.3	355,929	0.5	27	50,217	8.0	552,269	0.5	44
Disabled	15,268	19.9	172,991	0.7	78	17,262	22.5	193,153	0.5	30	10,397	13.5	120,741	0.6	47
	719	11.0	8,323	0.7	84	117	1.8	1,368	0.4	10	501	7.6	5,729	0.4	28
5 and younger	2,746	17.1	31,916	0.7	79	2,513	15.7	29,178	0.5	25	7,447	46.5	86,606	0.6	47
6-14	1,765	18.5	20,346	0.8	93	1,856	19.5	21,335	0.5	30	1,978	20.7	22,989	0.5	47
15-20	5,183	25.5	58,838	0.8	87	5,530	27.3	61,737	0.5	32	347	1.7	3,986	0.5	51
21-44	4,767	20.0	52,615	0.6	59	7,139	30.0	78,357	0.5	30	122	0.5	1,415	0.5	56
45-64	78	14.9	851	0.6	49	96	18.3	1,066	0.6	34	1	0.2	12	0.1	11
65-74	9	11.1	90	0.5	14	11	13.6	112	0.7	38	1	1.2	4	0.3	9
75-84	1	12.5	12	0.3	11	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	6,943	1.3	72,020	0.5	52	15,794	2.9	162,776	0.4	23	39,820	7.2	431,528	0.5	43
_	958	0.4	10,464	0.4	46	376	0.2	4,155	0.3	10	2,803	1.2	31,171	0.4	26
5 and younger	2,986	1.5	32,458	0.5	54	7,346	3.6	80,676	0.4	21	31,969	15.5	346,960	0.5	44
6-14	1,325	1.7	13,745	0.5	61	4,149	5.4	42,710	0.4	24	4,872	6.4	51,856	0.5	46
15-20	1,192	5.7	10,831	0.4	43	2,862	13.7	25,478	0.4	24	137	0.7	1,208	0.4	43
21-44	328	9.1	2,911	0.5	49	788	21.9	7,035	0.4	26	33	0.9	276	0.4	46
45-64	70	12.6	754	0.7	53	101	18.2	1,051	0.6	39	2	0.4	15	0.3	28
65-74	67	12.6	715	0.7	42	119	22.4	1,194	0.6	33	1	0.2	12	0.1	7
75-84	17	7.3	142	1.0	46	53	22.8	477	0.7	40	3	1.3	30	0.9	12
85 and older															
Unknown	0	0.0	0	0.0	0	1	1.8	12	0.7	27	2	3.6	24	0.5	43

Table ND7B Nondual Beneficiaries

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7B Nondual Beneficiaries

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE $^{a,\,b,\,c}$ NONDUAL BENEFICIARIES, GEORGIA, 2004

		DERMA	TOLOGICAL			-	ANT	TVIRAL			PAS	SSIVE IMM	UNIZING AG	ENTS	
		Users	Number of Benefit	Mean Number of Rx	Mean		Users	Number of Benefit	Mean Number of Rx	Mean		Users	Number of Benefit	Mean Number of Rx	
Beneficiary	Number of	as % of All	Months Among	per Benefit	Rx \$ per Benefit	Number of	as % of All	Months Among	per Benefit	Rx \$ per Benefit	Number of	as % of All	Months Among	per Benefit	Rx \$ per Benefit
Characteristics All	Users 406,231	Benes 27.0 %	Users 4,286,471	Month 0.2	Month \$7	Users 25,255	Benes 1.7 %	Users 260,680	Month 0.3	Month \$113	Users 3,420	Benes 0.2 %	Users 30,844	Month 0.6	Month \$797
Female	237,750	27.1	2,506,255	0.2	8	17,329	2.0	176,632	0.3	93	1,694	0.2	15,241	0.5	800
Disabled	27,787	34.7	323,279	0.2	9	5,120	6.4	57,581	0.4	171	392	0.5	3,937	0.6	1,095
	2,017	45.0	22,883	0.1	6	77	1.7	883	0.4	47	352	7.9	3,502	0.6	722
5 and younger	3,138	38.2	37,057	0.2	7	239	2.9	2,767	0.4	127	10	0.1	120	0.8	1,206
6-14	2,135	35.7	25,070	0.2	8	209	3.5	2,440	0.3	81	5	0.1	60	0.8	3,632
15-20	7,673	32.2	89,251	0.2	9	2,429	10.2	27,196	0.4	179	18	0.1	183	1.0	5,141
21-44	12,266	34.1	142,520	0.2	11	2,122	5.9	23,808	0.4	180	7	0.0	72	1.4	6,670
45-64	484	35.9	5,651	0.2	12	44	3.3	487	0.4	149	0	0.0	0	0.0	0
65-74	59	31.1	682	0.2	11	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	15	39.5	165	0.2	8	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	209,963	26.4	2,182,976	0.2	7	12,209	1.5	119,051	0.3	55	1,302	0.2	11,304	0.5	697
Other Eligibles	101,261	42.8	1,045,928	0.2	6	1,361	0.6	14,438	0.1	10	1,207	0.5	10,476	0.6	704
5 and younger	51,263	25.1	561,177	0.2	8	1,208	0.6	13,312	0.1	41	5	0.0	55	1.0	1,718
6-14	22,913	20.8	241,175	0.2	9	1,978	1.8	19,917	0.2	28	23	0.0	201	0.1	1,710
15-20	31,168	13.5	300,092	0.2	8	7,231	3.1	67,190	0.2	70	23 67	0.0	572	0.1	716
21-44	,		,		9			,			0				0
45-64	2,535	20.4	25,697	0.2		392	3.2	3,792	0.4	167	ŭ	0.0	0	0.0	
65-74	290	29.1	3,138	0.3	15	21	2.1	213	0.2	39	0	0.0	0	0.0	0
75-84	298	30.9	3,295	0.2	14	12	1.2	130	0.3	126	0	0.0	0	0.0	0
85 and older	235	45.4	2,474	0.2	9	6	1.2	59	0.1	8	0	0.0	0	0.0	0
Male	168,476	26.8	1,780,179	0.2	7	7,926	1.3	84,048	0.4	154	1,726	0.3	15,603	0.6	794
Disabled	19,263	25.1	221,642	0.2	9	4,614	6.0	48,773	0.6	235	405	0.5	4,193	0.6	921
Disableu	2,777	42.4	31,837	0.2	6	81	1.2	939	0.3	26	376	5.7	3,849	0.5	756
5 and younger	4,541	28.3	53,381	0.1	7	239	1.5	2,811	0.5	136	18	0.1	216	0.8	1,450
6-14	2,660	27.9	31,193	0.2	9	96	1.0	1,067	0.4	103	4	0.0	45	0.6	1,907
15-20	4,075	20.1	46,413	0.2	9	2,267	11.2	23,132	0.5	231	6	0.0	72	0.8	4,646
21-44	5,076	21.3	57,273	0.2	12	1,919	8.1	20,733	0.6	270	1	0.0	11	1.1	19,995
45-64	121	23.1	1,395	0.2	9	1,313	2.1	79	0.2	124	0	0.0	0	0.0	0
65-74	12	14.8	1,333	0.2	6	1	1.2	12	0.2	6	0	0.0	0	0.0	0
75-84	12	12.5	6	0.2	11	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	149,213	27.1		0.3	7	3,312		35,275	0.0	41	1,321	0.0	11,410	0.6	748
Other Eligibles	,		1,558,537			,	0.6	,			•		,		
5 and younger	96,152	39.6	984,695	0.2	6	1,483	0.6	15,842	0.1	9	1,313	0.5	11,325	0.6	725
6-14	38,099	18.5	418,149	0.1	7	1,039	0.5	11,414	0.2	38	5	0.0	53	1.3	2,724
15-20	12,603	16.5	133,787	0.2	11	439	0.6	4,598	0.2	39	1	0.0	11	1.1	3,301
21-44	1,553	7.4	13,895	0.2	10	241	1.2	2,306	0.3	161	2	0.0	21	0.9	6,486
45-64	408	11.3	3,659	0.2	10	89	2.5	888	0.6	364	0	0.0	0	0.0	0
65-74	152	27.3	1,706	0.3	13	11	2.0	111	0.1	25	0	0.0	0	0.0	0
75-84	174	32.8	1,919	0.2	12	5	0.9	60	0.2	30	0	0.0	0	0.0	0
85 and older	72	31.0	727	0.3	11	5	2.2	56	0.1	11	0	0.0	0	0.0	0
Unknown	5	9.1	37	0.1	7	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C Nondual Beneficiaries

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7C Nondual Beneficiaries

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, GEORGIA, 2004

		ANALGES	SICS - Narcoti	С			MISC. HEI	MATOLOGICA	\L			
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Reneficiaries	f Number of Benefit Months
All	342,029	22.7 %	3,474,016	0.2	\$7	6,186	0.4 %	66,919	0.6	\$317	1,503,848	
Female	262,164	29.9	2,629,774	0.2	6	3,710	0.4	40,760	0.6	75	876,144	7,599,979
Disabled	60,216	75.2	688,839	0.4	13	3,024	3.8	33,921	0.6	73	80,097	861,831
	407	9.1	4,693	0.1	1	3	0.1	28	1.4	167	4,484	46,840
5 and younger	1,179	14.3	13,727	0.1	1	5	0.1	60	0.8	1,402	8,220	92,225
6-14	2,175	36.3	25,240	0.2	2	7	0.1	84	0.5	25	5,987	66,230
15-20	20,914	87.8	239,808	0.3	12	297	1.2	3,355	0.5	67	23,811	
21-44	34,463	95.7	393,203	0.4	16	2,562	7.1	28,707	0.6	71	36,020	,
45-64	948	70.4	10,772	0.4	11	126	9.4	1,433	0.6	63	1,347	•
65-74	112	58.9	1,245	0.3	7	22	11.6	230	0.6	74	190	·
75-84	18	47.4	151	0.4	11	2	5.3	24	0.8	95	38	•
85 and older Other Eligibles	201,948	25.4	1,940,935	0.2	3	686	0.1	6,839	0.5	87	796,047	
Other Eligibles	7,802	3.3	85,828	0.1	1	4	0.0	43	0.5	4,079	236,479	, ,
5 and younger	14,192	7.0	155,437	0.1	1	3	0.0	36	0.1	515	204,141	
6-14	34,809	31.6	343,537	0.1	1	9	0.0	98	0.1	264	110,238	
15-20	135,360	58.8	1,259,503	0.1	4	254	0.0	2,497	0.1	53	230,295	,
21-44	8,746	70.4	85,676	0.2	8	220	1.8	2,497	0.4	54	12,417	, ,
45-64	428	43.0	4,512	0.3	7	60	6.0	644	0.5	47	996	,
65-74	419		4,512	0.3	11	94		986	0.5	63	963	,
75-84		43.5	-				9.8					,
85 and older	192	37.1	1,898	0.4	11	42	8.1	428	0.8	86	518	4,507
Male	79,863	12.7	844,218	0.2	8	2,476	0.4	26,159	0.6	693	627,649	5,724,000
Disabled	29,575	38.5	328,361	0.4	17	2,043	2.7	22,140	0.6	660	76,800	802,931
	741	11.3	8,625	0.1	1	19	0.3	220	0.8	5,608	6,552	9 69,367
5 and younger	1,876	11.7	21,999	0.1	1	36	0.2	404	0.6	6,860	16,019	179,046
6-14	2,152	22.6	24,897	0.2	3	28	0.3	311	0.5	12,755	9,534	104,474
15-20	9,296	45.8	103,423	0.3	15	170	0.8	1,879	0.5	2,805	20,290	
21-44	15,212	63.9	166,138	0.4	23	1,731	7.3	18,661	0.6	71	23,792	-
45-64	264	50.4	2,907	0.3	10	53	10.1	595	0.6	56	524	,
65-74	29	35.8	324	0.4	5	6	7.4	70	0.5	62	81	,
75-84	5	62.5	48	0.3	10	0	0.0	0	0.0	0	8	
85 and older Other Eligibles	50,288	9.1	515,857	0.2	3	433	0.1	4,019	0.6	875	550,849	
Other Eligibles	10,347	4.3	113,783	0.2	1	27	0.0	263	0.4	1,344	242,985	, ,
5 and younger	14,949	7.3	163,398	0.1	1	29	0.0	318	0.4	3,236	205,657	, ,
6-14	12,057	7.3 15.8	125,505	0.1	1	18	0.0	185	0.4	10,035	76,404	, ,
15-20	10,378	49.7	89,377	0.1	10	99	0.5	780	0.6	119	20,889	,
21-44	2,065	57.4	18,699	0.4	16	129	3.6	1,066	0.5	82	3,595	
45-64	2,065	36.9	2,119	0.4	9	48	3.6 8.6	541	0.5	67	5,595 556	•
65-74					9 4			647	0.7		531	,
75-84	207 80	39.0	2,209 767	0.3 0.5		60 23	11.3 9.9	219	0.7	68 78	232	,
85 and older	80	34.5	101	0.5	16	23	9.9	∠19	0.7	78	232	1,997
Unknown	2	3.6	24	0.1	0	0	0.0	0	0.0	0	55	288

Table ND7D Nondual Beneficiaries

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Table ND7D Nondual Beneficiaries

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, GEORGIA, 2004

Beneficiary		Number of Rx per Benefit	Number of All-Year Nursing	Benefit Months Among All- Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month	Facility Residents	Residents
All	\$447	7.3	2,191	22,475
Age				
0-64	490	7.5	1,479	15,304
65-74	443	7.5	246	2,667
75-84	355	6.9	231	2,281
85 and older	248	5.7	235	2,223
Unknown	0	0.0	0	0
Gender				
Female	453	7.6	1,239	12,977
Male	439	6.8	952	9,498
Unknown	0	0.0	0	0
Race				
White	454	7.7	1,037	10,574
African American	446	7	1,059	10,977
Other/unknown	369	7	95	924
Basis of Eligibility ^c				
Aged	335	6.6	558	5,454
Disabled	482	7.5	1,630	17,015
Adults	27	0.8	2	5
Children	0	0.0	1	1
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY NONDUAL BENEFICIARIES, GEORGIA, 2004

		er of Ranth Amo	•			er Bene Among	Users	:h		\$ per						Users	
Therapeutic Category	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	P Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.2	0.0	0.2	\$51	\$41	\$3	\$7	\$103	\$184	\$96	\$28	7,513	\$774,266	1,429	65.2 %	15,289
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.6	0.0	0.0	0.5	66	15	0	51	117	319	0	98	640	74,681	119	5.4	1,137
Endocrine/Metabolic Drugs	1.2	0.6	0.1	0.5	58	45	5	8	48	79	31	16	12,147	585,957	943	43.0	10,149
Cardiovascular Agents	2.1	0.6	0.1	1.4	70	45	2	23	33	72	31	16	33,644	1,125,266	1,540	70.3	16,008
Respiratory Agents	0.7	0.2	0.0	0.5	27	19	0	8	38	79	22	18	7,559	289,693	997	45.5	10,658
Gastrointestinal Agents	1.1	0.2	0.0	0.9	41	25	2	15	36	111	87	17	14,368	523,525	1,215	55.5	12,755
Genitourinary Agents	0.6	0.4	0.0	0.1	40	33	2	5	66	78	53	32	2,819	184,876	420	19.2	4,570
CNS Drugs	1.8	0.9	0.1	8.0	186	160	7	19	102	171	79	24	31,329	3,210,160	1,627	74.3	17,242
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.5	0.2	0.0	0.3	36	30	0	6	66	127	0	20	127	8,320	22	1.0	231
Neurological Agents	0.9	0.9	0.0	0.0	153	153	0	0	175	175	0	78	2,088	364,442	227	10.4	2,375
Analgesics and Anesthetics	1.2	0.4	0.0	0.7	55	42	2	11	47	101	66	15	14,714	697,516	1,207	55.1	12,740
Neuromuscular Agents	1.4	0.4	0.3	0.7	99	50	24	25	69	135	69	35	17,347	1,196,700	1,126	51.4	12,145
Nutritional Products	0.7	0.0	0.1	0.7	12	0	1	11	17	19	18	17	4,723	80,196	622	28.4	6,466
Hematological Agents	1.0	0.4	0.3	0.3	90	76	8	6	87	199	26	17	6,475	562,740	605	27.6	6,227
Topical Products	0.6	0.2	0.1	0.3	25	14	4	7	44	69	50	24	7,495	328,105	1,209	55.2	13,170
Miscellaneous Products	0.2	0.0	0.0	0.2	14	4	0	11	60	272	141	47	278	16,715	106	4.8	1,154
Unknown Therapeutic Category	0.5	0.0	0.0	0.0	10	0	0	0	22	0	0	0	642	13,902	120	5.5	1,343
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	163,908	10,037,060	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Georgia, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND9 Nondual Beneficiaries

TABLE ND.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP $^{a, b, c, d}$

NONDUAL BENEFICIARIES, GEORGIA, 2004

			Users		A	mong Users	
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$2,312,796	1,249	57.0 %	13,902	0.8	\$201	\$166
ANTICONVULSANT	1,010,901	1,200	54.8	13,203	1.0	75	77
ANTIDEPRESSANTS	757,278	1,372	62.6	14,801	0.8	62	51
ANTIDIABETIC	528,457	1,057	48.2	11,441	1.0	48	46
ULCER DRUGS	388,228	1,294	59.1	13,940	0.8	37	28
ANALGESICS - Narcotic MISC PSYCHOTHERAPEUTIC AND	363,193	1,272	58.1	13,376	0.7	38	27
NEUROLOGICAL	364,442	255	11.6	2,716	0.8	175	134
ANTIVIRAL	356,960	133	6.1	1,430	0.5	470	250
ANTIHYPERTENSIVE	325,635	1,157	52.8	12,273	0.8	33	27
ANTIHYPERLIPIDEMIC	286,109	383	17.5	4,184	0.8	90	68
Total	6,693,999	9,372		101,266	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, GEORGIA, 2004

	All Top 10 Dru	ug Groups		ANTIPS	SYCHOTICS			ANTICONVULSANT				
Beneficiary Characteristics	Number of Rx	Rx\$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	84,430	\$6,693,999	1,249	57.0 %	13,902	0.8	\$166	1,200	54.8 %	13,203	1.0	\$77
Female	51,294	3,957,400	732	59.1	8,212	0.8	166	685	55.3	7,583	1.0	76
Disabled	39,746	3,206,882	549	64.0	6,255	0.8	178	584	68.1	6,552	1.0	79
	34,892	2,877,556	480	63.8	5,483	0.9	183	524	69.7	5,872	1.0	83
64 or younger	3,878	263,177	57	67.9	628	0.8	145	49	58.3	566	0.9	51
65-74	886	60,038	11	61.1	132	0.9	138	11	61.1	114	1.1	45
75-84	90	6,111	1	25.0	12	0.7	122	0	0.0	0	0.0	0
85 and older Other Eligibles	11,548	750,518	183	48.0	1,957	0.8	126	101	26.5	1,031	1.0	58
•	2	77	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger	2,942	226,738	52	72.2	576	0.8	166	32	44.4	359	1.0	75
65-74	4,857	316,549	76	55.5	794	0.8	121	45	32.8	450	1.1	56
75-84	3,747	207,154	55	32.4	587	0.7	93	24	14.1	222	0.8	36
85 and older												
Male	33,136	2,736,599	517	54.3	5,690	8.0	168	515	54.1	5,620	1.0	77
Disabled	27,971	2,376,202	439	56.9	4,898	8.0	171	458	59.3	5,034	1.0	77
64 or younger	26,236	2,229,894	402	55.5	4,473	8.0	172	435	60.1	4,764	1.0	79
65-74	1,521	131,392	35	89.7	401	0.8	161	23	59.0	270	0.7	54
75-84	197	14,724	2	25.0	24	0.9	197	0	0.0	0	0.0	0
85 and older	17	192	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	5,165	360,397	78	43.3	792	0.8	147	57	31.7	586	1.1	74
64 or vounger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger 65-74	1,908	148,527	22	43.1	258	0.9	195	24	47.1	263	1.3	97
75-84	2,069	141,829	40	58.8	404	0.8	127	25	36.8	256	0.8	54
75-84 85 and older	1,188	70,041	16	26.7	130	8.0	112	8	13.3	67	1.1	61
	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	U	U	0.0	U	0.0	U	0	0.0	0	0.0	0

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, GEORGIA, 2004

		ANTIDE	PRESSANTS			-	ANTI	DIABETIC			ULCER DRUGS				
		Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean	
Beneficiary	Number of	Facility	Among	Number	Mean	Number of	Facility	Among		Mean	Number of	Facility	- 3	Number	Mean
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$
All	1,372	62.6 %	14,801	8.0	\$51	1,057	48.2 %	11,441	1.0	\$46	1,294	59.1 %	13,940	8.0	\$28
Female	841	67.9	9,249	0.8	51	715	57.7	7,725	1.0	45	742	59.9	8,096	0.8	28
Disabled	619	72.1	7,008	0.8	54	552	64.3	6,114	1.0	45	530	61.8	5,907	0.8	28
r	553	73.5	6,264	0.9	55	462	61.4	5,139	1.0	46	453	60.2	5,037	0.8	28
64 or younge	53	63.1	588	0.9	47	63	75.0	669	1.0	38	62	73.8	701	0.7	26
65-74	12	66.7	144	0.7	42	24	133.3	270	0.8	42	11	61.1	121	0.8	29
75-84	1	25.0	12	0.9	61	3	75.0	36	0.4	28	4	100.0	48	0.7	43
85 and older Other Eligibles	222	58.3	2,241	0.8	42	163	42.8	1,611	1.0	45	212	55.6	2,189	0.8	27
r	1	50.0	3	0.3	22	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	44	61.1	475	0.7	45	47	65.3	508	1.0	58	47	65.3	539	0.8	25
65-74	92	67.2	925	0.8	43	68	49.6	672	0.9	43	78	56.9	777	0.8	32
75-84	85	50.0	838	0.8	40	48	28.2	431	0.9	31	87	51.2	873	0.8	24
85 and older											_				
Male	531	55.8	5,552	0.8	51	342	35.9	3,716	1.0	50	552	58.0	5,844	8.0	28
Disabled	426	55.2	4,557	0.8	51	281	36.4	3,100	1.0	52	459	59.5	4,918	8.0	28
r 64 or vous	400	55.2	4,245	0.8	52	259	35.8	2,850	1.0	51	433	59.8	4,635	0.8	28
64 or younge	22	56.4	264	0.7	48	19	48.7	214	1.0	54	23	59.0	252	0.8	34
65-74	4	50.0	48	0.8	33	3	37.5	36	0.8	66	3	37.5	31	0.8	24
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	105	58.3	995	0.8	50	61	33.9	616	0.9	39	93	51.7	926	0.7	28
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	38	74.5	379	0.8	53	22	43.1	225	1.0	31	32	62.7	311	0.7	36
65-74	41	60.3	397	0.8	46	31	45.6	327	0.8	36	30	44.1	295	0.7	23
75-84	26	43.3	219	0.8	52	8	13.3	64	1.6	79	31	51.7	320	0.7	24
85 and older															
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, GEORGIA, 2004

_	ANALGESICS - Narcotic					MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					ANTIVIRAL				
Beneficiary Characteristics	Number of Users 1,272	Users as % of All-Year Nursing Facility Residents 58.1 %	Number of Benefit Months Among Users 13,376	Mean Number of Rx	Mean Rx \$	Number of Users 255	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users 2,716	Mean Number of Rx	Mean Rx \$	Number of Users 133	Users as % of All-Year Nursing Facility Residents 6.1 %	Number of Benefit Months Among Users 1,430	Mean Number of Rx	Mean Rx \$ \$250
Female	785	63.4	8,474	0.7	30	168	13.6	1,783	0.8	145	62	5.0	660	0.4	177
Disabled	592 520	69.0 69.1	6,504 5,702	0.8 0.8	32 33	79 56	9.2 7.4	903 637	0.7 0.7	183 217	51 48	5.9 6.4	535 521	0.5 0.5	215 220
64 or younge	60	71.4	678	0.6	33 27	16	19.0	182	0.7	217 97	3	3.6	14	0.3	51
65-74	11	61.1	112	0.6	14	7	38.9	84	0.8	107	0	0.0	0	0.0	0
75-84	1	25.0	12	0.3	3	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	193	50.7	1,970	0.6	23	89	23.4	880	0.8	105	11	2.9	125	0.0	11
Other Eligibles	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	48	66.7	544	0.6	28	8	11.1	87	0.8	87	2	2.8	24	0.1	4
65-74	67	48.9	680	0.8	25	45	32.8	440	0.8	108	6	4.4	65	0.2	16
75-84	78	45.9	746	0.5	18	36	21.2	353	0.8	106	3	1.8	36	0.1	8
85 and older															
Male	487	51.2	4,902	0.7	22	87	9.1	933	0.7	115	71	7.5	770	0.6	312
Disabled	396	51.3	4,035	0.7	23	46	6.0	491	0.8	130	66	8.5	711	0.6	337
64 or younge	377 14	52.1 35.9	3,827 148	0.7 0.5	24 21	41 4	5.7 10.3	436 48	0.8 0.6	134 85	65 1	9.0 2.6	699 12	0.7 0.1	343 1
65-74	3	35.9 37.5	36	0.5	3	4	10.3	46 7	2.0	65 167	0	0.0	0	0.1	0
75-84	2	200.0	24	0.3	2	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	91	50.6	867	0.2	17	41	22.8	442	0.0	97	5	2.8	59	0.0	8
Other Eligibles	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge '	28	54.9	281	0.4	14	11	21.6	124	0.7	98	2	3.9	24	0.2	3
65-74	40	58.8	399	0.5	8	19	27.9	196	0.7	96	0	0.0	0	0.0	0
75-84	23	38.3	187	1.1	43	11	18.3	122	0.8	98	3	5.0	35	0.1	12
85 and older Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

Table ND10C Nondual Beneficiaries

TABLE ND.10D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c, d} NONDUAL BENEFICIARIES, GEORGIA, 2004

		ANTIHYF	PERTENSIVE				ANTIHYF	PERLIPIDEMI	С			
		Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean		All-Year Nursing	Benefit Months Among All- Year Nursing
Beneficiary	Number of	Facility	Among	Number	Mean	Number of	Facility	Among		Mean	Facility	Facility
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Residents	Residents
All	1,157	52.8 %	12,273	0.8	\$27	383	17.5 %	4,184	0.8	\$68	2,191	22,475
Female	658	53.1	7,054	0.8	26	226	18.2	2,470	0.8	66	1,239	12,977
Disabled	461	53.7	4,994	0.8	27	168	19.6	1,882	0.8	69	858	9,184
	381	50.7	4,113	0.8	27	147	19.5	1,644	0.8	69	752	8,009
64 or younger	66	78.6	732	0.7	30	16	19.0	188	0.8	69	84	932
65-74	11	61.1	113	0.8	23	5	27.8	50	0.6	52	18	195
75-84	3	75.0	36	0.6	23	0	0.0	0	0.0	0	4	48
85 and older Other Eligibles	197	51.7	2,060	0.8	23	58	15.2	588	0.7	56	381	3,793
_	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	5
64 or younger	43	59.7	457	0.8	21	11	15.3	123	0.7	65	72	796
65-74	80	58.4	814	0.8	24	30	21.9	271	0.7	65	137	1,352
75-84	74	43.5	789	0.8	23	17	10.0	194	0.6	38	170	1,640
85 and older												
Male	499	52.4	5,219	0.8	27	157	16.5	1,714	0.8	72	952	9,498
Disabled	403	52.2	4,221	0.8	28	131	17.0	1,437	0.8	73	772	7,831
64 or younger	367	50.7	3,796	0.8	29	123	17.0	1,341	0.8	72	724	7,289
65-74	31	79.5	365	0.7	18	7	17.9	84	0.7	70	39	439
75-84	4	50.0	48	0.9	38	1	12.5	12	1.4	181	8	91
	1	100.0	12	1.0	12	0	0.0	0	0.0	0	1	12
85 and older Other Eligibles	96	53.3	998	0.8	24	26	14.4	277	0.8	69	180	1,667
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
65-74	36	70.6	392	0.8	21	10	19.6	111	1.0	91	51	500
75-84	36	52.9	375	0.9	28	12	17.6	118	0.8	63	68	643
85 and older	24	40.0	231	0.7	23	4	6.7	48	0.4	32	60	523
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,336 beneficiaries who were in nursing facilities for part of their enrollment and their 13,239 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

GEORGIA, 2004

	Number of	Percentage of							
		Beneficiaries with at	Number of Part	Total Number Pa	art D Excluded			Part D Excluded Rx	
Beneficiary	at Least One Part	Least One Part D	D Excluded Rx	Part D	Rx \$ per	Total Part D		as a Percentage of	Total Number of
Characteristics	D Excluded Rx	Excluded Rx	per Beneficiary	Excluded Rx	Beneficiary	Excluded Rx \$	Excluded Rx	All Nondual Rx \$	Beneficiaries
All	435,419	29.0 %	0.8	1,202,350	\$17	\$25,734,148	\$21	3.8 %	1,503,848
Age									
5 and younger	207,895	42.4	1.1	541,203	21	10,264,972	19	9.3	490,540
6-14	101,519	23.4	0.5	216,694	13	5,796,181	27	4.4	434,047
15-20	40,304	19.9	0.4	88,535	11	2,312,166	26	3.4	202,165
21-44	56,757	19.2	0.6	172,220	14	4,190,684	24	2.3	295,285
45-64	26,923	35.5	2.2	169,660	40	3,015,631	18	1.7	75,824
65-74	1,164	34.0	2.4	8,218	27	93,796	11	1.3	3,424
75-84	570	32.3	2.2	3,931	23	40,118	10	1.3	1,765
85 and older	287	36.1	2.4	1,889	26	20,600	11	1.7	796
Unknown	0	0.0	0.0	0	0	0	0	0.0	2
Basis of Eligibility ^c									
Aged	1,088	29.1	1.9	7,063	20	75,015	11	1.2	3,737
Disabled	53,353	34.0	1.9	290,940	52	8,158,345	28	2.4	156,897
Adults	57,081	18.9	0.4	135,273	7	2,141,618	16	2.1	302,427
Children	323,137	31.1	0.7	766,395	15	15,323,357	20	6.7	1,038,063
Unknown	760	27.9	1.0	2,679	13	35,813	13	0.9	2,724
Gender									
Female	250,037	28.5	0.8	699,829	17	14,518,591	21	3.7	876,145
Male	185,373	29.5	0.8	502,497	18	11,215,025	22	3.9	627,650
Unknown	9	17.0	0.5	24	10	532	22	9.3	53
Race									
White	208,949	33.9	1.0	602,994	21	12,897,003	21	4.0	615,507
African American	181,949	24.3	0.6	460,130	12	9,354,141	20	3.5	748,707
Other/unknown	44,521	31.9	1.0	139,226	25	3,483,004	25	3.8	139,634
Use of Nursing									
Facilities ^d									
Entire year	1,312	59.9	6.4	13,953	83	181,533	13	1.8	2,191
Part year	933	69.8	5.6	7,540	83	110,623	15	1.9	1,336
None	433,174	28.9	0.8	1,180,857	17	25,441,992	22	3.8	1,500,321
Maintenance									
Assistance Status									
Cash	150,981	29.2	1.0	520,009	23	11,980,137	23	2.8	517,508
Medically needy	1,220	29.0	1.3	5,597	109	456,388	82	6.7	4,205
Poverty related	208,425	28.4	0.7	482,051	13	9,224,735	19	6.2	734,957
Other/unknown	74,793	30.3	8.0	194,693	16	4,072,888	21	4.2	247,178

Table ND11 Nondual Beneficiaries

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

GEORGIA, 2004

Beneficiary	Number Rx per	Rx \$ per		Barbiturate \$ per Bei		Number of
Characteristics	Benefit Month	Benefit Month	\$ per Rx	Benefit Month	Benefit Month	Benefit Months
All	0.1	\$2	\$21	\$0	\$0	13,324,267
Age						
5 and younger	0.1	2	19	0	0	4,340,719
6-14	0.1	1	27	0	0	4,155,228
15-20	0.1	1	26	0	0	1,769,478
21-44	0.1	2	24	0	0	2,263,922
45-64	0.2	4	18	0	1	736,672
65-74	0.2	3	11	0	1	34,256
75-84	0.2	2	10	0	1	17,030
85 and older	0.3	3	11	0	1	6,955
Unknown	0.0	0	0	0	0	7
Basis of Eligibility ^c						
Aged	0.2	2	11	0	1	33,873
Disabled	0.2	5	28	0	1	1,664,762
Adults	0.1	1	16	0	0	2,162,337
Children	0.1	2	20	0	0	9,436,905
Unknown	0.1	1	13	0	0	26,390
Gender						
Female	0.1	2	21	0	0	7,599,984
Male	0.1	2	22	0	0	5,724,002
Unknown	0.1	2	22	0	0	281
Race						
White	0.1	2	21	0	0	5,192,291
African American	0.1	1	20	0	0	6,897,166
Other/unknown	0.1	3	25	0	1	1,234,810
Use of Nursing						
Facilities ^d						
Entire year	0.6	8	13	1	3	22,475
Part year	0.6	8	15	0	3	13,239
None	0.1	2	22	0	0	13,288,553
Maintenance Assistance Status						
Cash	0.1	2	23	0	0	4,921,279
Medically needy	0.2	19	82	0	1	23,707
Poverty related	0.1	1	19	0	0	6,278,461
Other/unknown	0.1	2	21	0	0	2,100,820

Table ND12 Nondual Beneficiaries

- a. Table ND.12 includes the beneficaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c} GEORGIA, 2004

				Rx \$ as a Percentage of All			Number Rx as a Percentage of All
				Part D			Part D
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Excluded Rx \$	Total Number Rx.	\$ per Rx	Excluded Rx
All	492,016	\$52	\$25,734,148	100.0 %	1,202,350	\$21	100.0 %
Anorexia or weight loss/gain	76	301	22,850	0.1	201	114	0.0
Fertility drugs	1	172	172	0.0	4	43	0.0
Drugs for cosmetic purposes	226	15	3,438	0.0	378	9	0.0
Cough and cold medications	328,526	45	14,932,731	58.0	731,960	20	60.9
Vitamins and minerals	21,470	82	1,759,577	6.8	93,552	19	7.8
Non-prescription drugs	74,861	12	892,963	3.5	149,258	6	12.4
Barbiturates	3,148	47	146,857	0.6	25,617	6	2.1
Benzodiazepines	41,178	78	3,218,629	12.5	153,932	21	12.8
Other Part D Excl Rx Drugs	22,530	211	4,756,931	18.5	47,448	100	3.9

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, GEORGIA, 2004

Beneficiary			Number of Be	neficiaries			Number of Benefit Months					
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	1,503,848	3,737	156,897	302,427	1,038,063	2,724	13,324,267	33,873	1,664,762	2,162,337	9,436,905	26,390
Age												
5 and younger	490,540	0	11,036	83	479,419	2	4,340,719	0	116,207	466	4,224,044	2
6-14	434,047	0	24,239	235	409,573	0	4,155,228	0	271,271	1,404	3,882,553	0
15-20	202,165	0	15,521	38,127	148,430	87	1,769,478	0	170,704	272,991	1,325,072	711
21-44	295,285	0	44,101	249,222	598	1,364	2,263,922	0	471,074	1,774,655	4,886	13,307
45-64	75,824	0	59,812	14,730	22	1,260	736,672	0	611,641	112,623	137	12,271
65-74	3,424	1,519	1,871	19	4	11	34,256	13,501	20,493	135	28	99
75-84	1,765	1,489	271	4	1	0	17,030	14,066	2,921	31	12	0
85 and older	796	729	46	6	15	0	6,955	6,306	451	27	171	0
Unknown	2	0	0	1	1	0		0	0	5	2	0
Gender												
Female	876,145	2,434	80,097	277,491	513,402	2,721	7,599,984	22,164	861,831	2,004,943	4,684,669	26,377
Male	627,650	1,302	76,800	24,936	524,609	3	7 5,724,002	11,708	802,931	157,394	4,751,956	13
Unknown	53	1	0	0	52	0	281	1	0	0	280	0
Race												
White	615,507	1,384	53,911	135,977	422,757	1,478	5,192,291	11,435	560,598	885,926	3,719,954	14,378
African American	748,707	979	69,046	157,817	519,931	934	6,897,166	8,618	740,085	1,230,028	4,909,614	8,821
Other/unknown	139,634	1,374	33,940	8,633	95,375	312	1,234,810	13,820	364,079	46,383	807,337	3,191
Use of Nursing Facilities ^c												
Entire year	2,191	558	1,630	2	1	0	22,475	5,454	17,015	5	1	0
Part year	1,336	265	1,059	7	2	3	13,239	2,365	10,789	54	11	20
None	1,500,321	2,914	154,208	302,418	1,038,060	2,721	13,288,553	26,054	1,636,958	2,162,278	9,436,893	26,370
Maintenance Assistance Status												
Cash	517,508	1,391	133,609	136,443	246,065	0	4,921,279	15,197	1,470,661	1,063,239	2,372,182	0
Medically needy	4,205	876	3,273	4	52	0	23,707	6,689	16,841	5	172	0
Poverty related	734,957	27	72	114,532	617,602	2,724	6,278,461	237	684	655,633	5,595,517	26,390
Other/unknown	247,178	1,443	19,943	51,448	174,344	0	2,100,820	11,750	176,576	443,460	1,469,034	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,503,848	3,737	156,897	302,427	1,038,063	2,724	13,324,267	33,873	1,664,762	2,162,337	9,436,905	26,390
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0

0 0

0

0

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, GEORGIA, 2004

	Beneficiarie Benefit Months in Ce		Included in Cell K	of Table 1	Excluded from Cell K	of Table 1
	Number of Nu Beneficiaries	umber of Benefit Months	Number of Nu Beneficiaries	umber of Benefit Months	Number of Num Beneficiaries	nber of Benefit Months
All	1,503,848	13,324,267	1,503,848	13,324,267	0	0
Fee-for-service (FFS) all year	1,503,848	13,324,267	1,503,848	13,324,267	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2004 file for Georgia, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.